Applied Genetic Technologies Corporation, (AGTC), a privately-held, clinical stage biotechnology company developing gene therapy products to treat rare retinal diseases, announced today that it has secured $37.5 million in a Series B round of financing.
Alta Partners and S.R. One, Limited led the financing, with new investor Osage University Partners joining existing investors InterWest,Intersouth Partners and MedImmune Ventures in the round. The funding will allow AGTC to continue development of its Phase 2 program in Alpha-1 Antitrypsin Deficiency (Alpha-1) and initiate full development of potential treatments for two orphan ophthalmology indications, Achromatopsia (ACHM) and X-Linked Rentinoschisis (XLRS).
{iframe}http://baltimore.citybizlist.com/article/medimmune-ventures-joins-375m-series-b-agtc{/iframe}